Division of Cardiovascular Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, United States.
Vascul Pharmacol. 2012 May-Jun;56(5-6):288-96. doi: 10.1016/j.vph.2012.02.010. Epub 2012 Feb 23.
Peripheral arterial disease (PAD) is characterized by reduced limb blood flow due to arterial obstruction. Current treatment includes surgical or endovascular procedures, the failure of which may result in amputation of the affected limb. An emerging therapeutic approach is cell therapy to enhance angiogenesis and tissue survival. Small clinical trials of adult progenitor cell therapies have generated promising results, although large randomized clinical trials using well-defined cells have not been performed. Intriguing pre-clinical studies have been performed using vascular cells derived from human embryonic stem cells (hESC) or human induced pluripotent stem cells (hiPSCs). In particular, hiPSC-derived vascular cells may be a superior approach for vascular regeneration. The regulatory roadmap to the clinic will be arduous, but achievable with further understanding of the reprogramming and differentiation processes; with meticulous attention to quality control; and perseverance.
外周动脉疾病（PAD）的特征是由于动脉阻塞导致肢体血液流量减少。目前的治疗方法包括手术或血管内治疗，但这些方法的失败可能导致受影响的肢体被截肢。一种新兴的治疗方法是细胞疗法，以增强血管生成和组织存活。成人祖细胞疗法的小型临床试验已经取得了有希望的结果，尽管尚未进行使用明确细胞的大型随机临床试验。使用源自人类胚胎干细胞（hESC）或人类诱导多能干细胞（hiPSC）的血管细胞进行了有趣的临床前研究。特别是，hiPSC 衍生的血管细胞可能是血管再生的一种更好的方法。通向临床的监管道路将是艰巨的，但随着对重编程和分化过程的进一步了解、对质量控制的细致关注以及坚持不懈，这是可以实现的。
